BioCentury Emerging Company Profile- WOUND-UP BACTERIA
Ilya Pharma and our innovative drug candidates was featured by BioCentury. We are very happy to be selected as an emerging company to keep track of!
In press
Our research applauded in Cell Host and Microbe
”Time heals all wounds...... but wounds heal faster with Lactobacillus” is the title of a commentary to our preclinical results (Vågesjö et al. 2018 PNAS) published by the very prestigious journal Cell-Host and Microbe. The authors summarizes our demonstration of a feasible and translatable therapeutic approach acceleration of wound healing with topical application of CXCL12-producing Lactobacilli and applauds the approach and the first steps in the drug development program. Chronic non-healing wounds represent a significant clinical problem and cost the healthcare system $19 billion annually. Our developed drug candidate being an advanced therapeutic medicinal product, is in the article referred to as a ”promising technology for the unsolved problem of delayed cutaneous wound healing”.
BioCentury recognises the clinical importance of the innovative next generation biologis developed by Ilya Pharma
BioCentury is an American platform that publishes new in science, biotech and pharma ranging from academic discoveries, results from clinical trials to multibillion dollar deals in the industry.
New technology for accelerated wound healing discovered
Uppsala university highlights the research, proof of concept and mechanism of action, published in highly ranked scientific journal PNAS, of the innovative drug candidates to treat wounds now developed by Ilya Pharma.
The medical research behind the innovation in Ilya Pharma featured in TV programme about new and important science, Vetenskapen Värld
Starts at minute 28.
Uppsala exploderar av livsviktiga företag
CEO Evelina Vågesjö gives a presentation and an interview at NGM
Watch Evelina presenting ILYA Pharma´s core invention, how it is used to accelerate wound healing and the development plan the next year. Ilya Pharma is developing the next generation live biotherapeutical products for treatment of different skin wounds and also indications in the gastrointestinal tract.